Amgen secures $70m in biosimilar clash with Hospira

Amgen has secured $70 million in damages from a jury in a biosimilar dispute with Hospira.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Hospira suffers setback as two patents invalidated

21 December 2018 A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.

Americas

Hospira appeals against $70m Amgen verdict

2 October 2017 Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.

Americas

Federal Circuit rejects Amgen biosimilar discovery request

11 August 2017 The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.

More on this story

Big Pharma

Hospira suffers setback as two patents invalidated

21 December 2018 A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.

Americas

Hospira appeals against $70m Amgen verdict

2 October 2017 Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.

Americas

Federal Circuit rejects Amgen biosimilar discovery request

11 August 2017 The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.

More on this story

Big Pharma

Hospira suffers setback as two patents invalidated

21 December 2018 A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.

Americas

Hospira appeals against $70m Amgen verdict

2 October 2017 Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.

Americas

Federal Circuit rejects Amgen biosimilar discovery request

11 August 2017 The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.